NeoGenomics Reports Third Quarter Financial Results

The Fort Myers-based company recorded a quarterly loss of $7.5 million amid $209.3 million in total revenue.

Updated on Oct. 28, 2026 in Corporate Finance

Isometric editorial illustration of a single lab centrifuge tube on a minimalist workbench, representing corporate financial data. — NeoGenomics reported a third-quarter net loss of $7.5 million for 2026, despite generating total revenue of $209.3 million. AI Illustration. Upload story photo >

Live Poll

Does a company beating earnings estimates make you more confident in the current stock market?

NeoGenomics announced a net loss of $7.5 million for the third quarter of 2026. The company generated $209.3 million in revenue during this period.

Why it matters

Understanding these financial results provides insight into the operational performance of the Fort Myers-based firm. The figures reflect the company's current standing as it manages costs and revenue streams.

NeoGenomics reported a net loss of 6 cents per share, though adjusted earnings reached 7 cents per share. The company currently expects full-year earnings to fall between 21 cents and 22 cents per share.

The players

NeoGenomics

This is a medical technology company headquartered in Fort Myers that specializes in cancer genetics testing and information services.

The details

The results were calculated by adjusting for stock option expenses and amortization costs. This financial update highlights the company's fiscal position as it navigates the 2026 business cycle.

The financial results cover the third quarter of 2026.

Market Dynamics

This earnings report reflects the ongoing volatility often seen in the biotech sector as firms balance high research costs against revenue growth. It follows the broader trend of companies adhering to strict financial transparency protocols mandated by the Sarbanes-Oxley Act of 2002.

Shareholders and potential investors should note the discrepancy between the net loss and the adjusted earnings per share. These figures provide a baseline for assessing the company's valuation and potential future profitability.

The takeaway

Investors should focus on the gap between the net loss and the adjusted earnings per share when evaluating the company's fiscal health. Monitoring the full-year guidance of 21 to 22 cents per share will be essential for gauging performance through the end of the year.